4D Molecular Shares Rise Premarket on Partnership With Otsuka
By Colin Kellaher
Shares of 4D Molecular Therapeutics moved higher in premarket trading Friday after the biotechnology company said it formed a partnership potentially worth hundreds of millions of dollars with Japan's Otsuka Pharmaceutical.
4D late Thursday said it will grant Otsuka exclusive rights to develop and commercialize its 4D-150 drug candidate for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, in Japan, China, Australia and other Asia-Pacific markets.
4D said it will receive an $85 million upfront cash payment from Otsuka and expects to receive at least $50 million of cost sharing from its partner over the next three years for development activities supporting global registration.
The Emeryville, Calif., company said it is also eligible to receive up to $336 million in regulatory and commercial milestone payments, along with royalties on product sales.
4D shares, which closed Thursday at $11.32, were recently up 10% to $12.49 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 31, 2025 07:14 ET (11:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States